Literature DB >> 26050543

Corneal High-Order Aberrations and Backscatter in Fuchs' Endothelial Corneal Dystrophy.

Katrin Wacker1, Jay W McLaren1, Sejal R Amin1, Keith H Baratz1, Sanjay V Patel2.   

Abstract

PURPOSE: Suboptimal visual acuity after endothelial keratoplasty has been attributed to increased anterior corneal high-order aberrations (HOAs). In this study, we determined anterior and posterior corneal HOAs over a range of severity of Fuchs' endothelial corneal dystrophy (FECD).
DESIGN: Cross-sectional study. PARTICIPANTS: A total of 108 eyes (62 subjects) with a range of severity of FECD and 71 normal eyes (38 subjects).
METHODS: All corneas were examined by using slit-lamp biomicroscopy to determine the severity of FECD versus normality. Fuchs' endothelial corneal dystrophy corneas were categorized as mild, moderate, or advanced according to the area and confluence of guttae and the presence of clinically visible edema. Normal corneas were devoid of any guttae. Wavefront errors from the anterior and posterior corneal surfaces were derived from Scheimpflug images and expressed as Zernike polynomials through the sixth order over a 6-mm diameter optical zone. Backscatter from the anterior 120 μm and posterior 60 μm of the cornea also was measured from Scheimpflug images and was standardized to a fixed scatter source. Variables were compared between FECD and control eyes by using generalized estimating equation models to adjust for age and correlation between fellow eyes. MAIN OUTCOME MEASURES: High-order aberrations, expressed as root mean square of wavefront errors, and backscatter of the anterior and posterior cornea.
RESULTS: Total anterior corneal HOAs were increased in moderate (0.61±0.27 μm, mean ± standard deviation; P = 0.01) and advanced (0.66±0.28 μm; P = 0.01) FECD compared with controls (0.47±0.16 μm). Total posterior corneal HOAs were increased in mild (0.22±0.09 μm; P = 0.017), moderate (0.22±0.08 μm; P < 0.001), and advanced (0.23±0.09 μm; P < 0.001) FECD compared with controls (0.16±0.03 μm). Anterior and posterior corneal backscatter were higher for all severities of FECD compared with controls (P ≤ 0.02, anterior; P ≤ 0.001, posterior).
CONCLUSIONS: Anterior and posterior corneal HOAs and backscatter are higher than normal even in early stages of FECD. The early onset of HOAs in FECD might contribute to the persistence of HOAs and incomplete visual rehabilitation after endothelial keratoplasty.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26050543      PMCID: PMC4516693          DOI: 10.1016/j.ophtha.2015.05.005

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  37 in total

1.  Standardization of corneal haze measurement in confocal microscopy.

Authors:  Jay W McLaren; William M Bourne; Sanjay V Patel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

2.  Retinal point-spread function after corneal transplantation for Fuchs' dystrophy.

Authors:  Loren S Seery; Jay W McLaren; Katrina M Kittleson; Sanjay V Patel
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-22       Impact factor: 4.799

3.  Measuring corneal thickness with the ConfoScan 4 and z-ring adapter.

Authors:  Jay W McLaren; Cherie B Nau; Sanjay V Patel; William M Bourne
Journal:  Eye Contact Lens       Date:  2007-07       Impact factor: 2.018

4.  The effect of corneal light scatter on vision after descemet stripping with endothelial keratoplasty.

Authors:  Sanjay V Patel; Keith H Baratz; David O Hodge; Leo J Maguire; Jay W McLaren
Journal:  Arch Ophthalmol       Date:  2009-02

5.  Corneal wavefront errors 24 months after deep lamellar endothelial keratoplasty and penetrating keratoplasty.

Authors:  Jay W McLaren; Sanjay V Patel; William M Bourne; Keith H Baratz
Journal:  Am J Ophthalmol       Date:  2009-03-19       Impact factor: 5.258

6.  Anterior keratocyte depletion in fuchs endothelial dystrophy.

Authors:  Laura A Hecker; Jay W McLaren; Lori A Bachman; Sanjay V Patel
Journal:  Arch Ophthalmol       Date:  2011-01-10

7.  3-D characterization of the corneal shape in Fuchs dystrophy and pseudophakic keratopathy.

Authors:  Isabelle Brunette; Denis Sherknies; Mark A Terry; Miguel Chagnon; Jean-Louis Bourges; Jean Meunier
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-05       Impact factor: 4.799

8.  Corneal aberrations and visual acuity after laser in situ keratomileusis: femtosecond laser versus mechanical microkeratome.

Authors:  Ramón Calvo; Jay W McLaren; David O Hodge; William M Bourne; Sanjay V Patel
Journal:  Am J Ophthalmol       Date:  2010-03-15       Impact factor: 5.258

9.  Normative database for corneal backscatter analysis by in vivo confocal microscopy.

Authors:  Toine Hillenaar; Roger H H Cals; Paul H C Eilers; René J Wubbels; Hugo van Cleynenbreugel; Lies Remeijer
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-21       Impact factor: 4.799

10.  Pentacam characterization of corneas with Fuchs dystrophy treated with Descemet membrane endothelial keratoplasty.

Authors:  Robert O Kwon; Marianne O Price; Francis W Price; Renato Ambrósio; Michael W Belin
Journal:  J Refract Surg       Date:  2010-02-15       Impact factor: 3.573

View more
  19 in total

1.  Corneal Optical Changes Associated with Induced Edema in Fuchs Endothelial Corneal Dystrophy.

Authors:  Katrin Wacker; Jay W McLaren; Katrina M Kane; Sanjay V Patel
Journal:  Cornea       Date:  2018-03       Impact factor: 2.651

2.  [The German version of the Visual Function and Corneal Health Status (V‑FUCHS): a Fuchs dystrophy-specific visual disability instrument].

Authors:  Viviane Grewing; Marianne Fritz; Claudia Müller; Daniel Böhringer; Thomas Reinhard; Sanjay V Patel; Katrin Wacker
Journal:  Ophthalmologe       Date:  2020-02       Impact factor: 1.059

Review 3.  Fuchs endothelial corneal dystrophy and corneal endothelial diseases: East meets West.

Authors:  Y Q Soh; Viridiana Kocaba; Mauricio Pinto; Jodhbir S Mehta
Journal:  Eye (Lond)       Date:  2019-07-02       Impact factor: 3.775

4.  Scheimpflug Corneal Densitometry Values and Severity of Guttae in Relation to Visual Acuity in Fuchs Endothelial Corneal Dystrophy.

Authors:  Khushali Shah; Allen O Eghrari; Elizabeth A Vanner; Terrence P O'Brien; Ellen H Koo
Journal:  Cornea       Date:  2021-06-15       Impact factor: 3.152

5.  Influences on rebubble rate in Descemet's membrane endothelial keratoplasty.

Authors:  Keegan B Mechels; Michael D Greenwood; Ramu G Sudhagoni; John P Berdahl
Journal:  Clin Ophthalmol       Date:  2017-12-05

Review 6.  Perspective of Future Potent Therapies for Fuchs Endothelial Corneal Dystrophy.

Authors:  Naoki Okumura; Ryousuke Hayashi; Noriko Koizumi
Journal:  Open Ophthalmol J       Date:  2018-07-23

7.  Measuring Corneal Haze by Using Scheimpflug Photography and Confocal Microscopy.

Authors:  Jay W McLaren; Katrin Wacker; Katrina M Kane; Sanjay V Patel
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-01-01       Impact factor: 4.799

8.  Corneal Hydration Control in Fuchs' Endothelial Corneal Dystrophy.

Authors:  Katrin Wacker; Jay W McLaren; Katrina M Kane; Keith H Baratz; Sanjay V Patel
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-09-01       Impact factor: 4.799

9.  Feasibility of cell-based therapy combined with descemetorhexis for treating Fuchs endothelial corneal dystrophy in rabbit model.

Authors:  Naoki Okumura; Daiki Matsumoto; Yuya Fukui; Masataka Teramoto; Hirofumi Imai; Tetta Kurosawa; Tomoki Shimada; Friedrich Kruse; Ursula Schlötzer-Schrehardt; Shigeru Kinoshita; Noriko Koizumi
Journal:  PLoS One       Date:  2018-01-16       Impact factor: 3.240

10.  Trinucleotide repeat expansion length as a predictor of the clinical progression of Fuchs' Endothelial Corneal Dystrophy.

Authors:  Yu Qiang Soh; Gary Peh Swee Lim; Hla Myint Htoon; Xin Gong; V Vinod Mootha; Eranga Nishanthie Vithana; Viridiana Kocaba; Jodhbir Singh Mehta
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.